The White House added nine more pharmaceutical manufacturers to its most-favored-nation pricing program on Monday, and the running total is the part worth reading. Twenty-six companies have now signed, and the administration says they account for 89% of the branded drug market in the United States.
A year ago the number was zero. The instrument that changed it was not a bill.
Nine Mid-Sized Manufacturers and the Diseases on the List
The nine companies announced Monday are Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals and UCB, mid-sized manufacturers rather than the household-name giants that signed first. The White House said the agreements cut prices on treatments for hemophilia, Parkinson’s disease, macular degeneration, glaucoma, liver disease, skin conditions and several forms of cancer.
That disease list is the strategic point. The first wave of most-favored-nation deals, running from Pfizer in September 2025 through the seventeen largest manufacturers, covered the blockbusters: the weight-loss drugs, the diabetes drugs, the products with television campaigns behind them. Monday’s nine reach into the specialty and rare-disease shelf, where a single therapy can carry a six-figure annual price and where almost no political attention has ever landed. The administration also secured a commitment from the nine to invest at least $19.6 billion collectively in American manufacturing in the near term, and to donate active pharmaceutical ingredients to a federal stockpile: 163 tons of the anticonvulsant levetiracetam from UCB, 45 metric tons of the antibiotic metronidazole from Teva, 71.4 tons of clindamycin from Sun Pharma, 25 kilograms of the transplant immunosuppressant tacrolimus from Astellas.
Every State Medicaid Program Gets the Foreign Price
The provision with the widest reach is the least glamorous. Under the agreements, every state Medicaid program in the country gains access to most-favored-nation prices on the nine companies’ products, the same prices those firms charge in Germany, Japan or Britain, rather than the American list price built on decades of foreign price controls.
The Council of Economic Advisers put a number on that channel in May, projecting $64.3 billion in combined federal and state savings over ten years from making existing drugs available to Medicaid at most-favored-nation prices. The same report projected $529 billion over a decade from the separate commitment that new drugs launch in the United States at prices comparable to other high-income countries, and estimated that uninsured users of GLP-1 weight-loss drugs would save roughly $3,000 a year while couples undergoing in-vitro fertilization would save more than $6,000. Those are projections written by the administration’s own economists, and they should be read as such. They are also the only detailed public accounting anyone has produced.
The 100% Tariff That Makes “Voluntary” Work
Every one of these agreements is formally voluntary, a word that has done a great deal of quiet work in the coverage. The reason twenty-six manufacturers volunteered is an executive order Trump signed on April 2 titled “Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States,” which found that imported pharmaceutical products threaten national security and built a tariff schedule around that finding.
The schedule is the leverage. In its April analysis of the order, the law firm Sidley Austin laid out the tiers: zero tariffs for companies that enter most-favored-nation pricing agreements and commit to onshoring production, zero on generics and biosimilars, 15% on products from allied jurisdictions including the European Union, Japan, Korea and Switzerland, 20% for firms with approved domestic manufacturing plans — and 100% on patented pharmaceutical products and ingredients for everyone else. A company choosing between matching its Berlin price in Boston and paying a hundred percent duty at the border is making a voluntary decision in roughly the sense that a driver volunteers to stop at a red light.
That is the honest description of what happened, and it is also the argument for it. Congress spent two decades failing to close the gap between what Americans pay for a patented medicine and what a German pays for the identical molecule. Trade authority closed a large part of it in under a year, without a floor vote, by making foreign price controls expensive for the manufacturers that had been quietly financing them out of American wallets.
What the $600 Billion Figure Is, and What It Is Not
The headline number attached to Monday’s announcement is $600 billion, which the Council of Economic Advisers estimates as the total savings from the most-favored-nation deals over the next decade. It is an estimate, not a receipt. It rests on ten-year projections built from agreements whose full terms have never been published, and the administration has not released the executed contracts.
The figures the White House presents as already banked are smaller and more concrete. It says patients have saved more than $700 million through TrumpRx.gov since the direct-to-consumer site launched in February. It says that after seniors without GLP-1 coverage for obesity gained access in July at $50 a month, more than 500,000 of them saved a combined $216 million in the program’s first two months. Those are administration figures rather than audited ones, and no outside body has verified them. They are also specific enough to be checked later, which is more than most Washington savings claims ever offer.
Congress Has Codified None of It
The genuine vulnerability here is not the size of the discounts. It is that all of them rest on executive action and can be undone by executive action. The Council of Economic Advisers said in May that the administration was working with Congress to write the voluntary agreements into law precisely so patients keep the discounts, and Trump used Monday’s announcement to press lawmakers again, calling on them to enact his Great Healthcare Plan.
Lawmakers have not obliged. Sidley Austin reported in April that bills supporting most-favored-nation pricing had been introduced in the House by members of both parties and referred to committee, and judged that such legislation was unlikely to pass this year. Two proposed Medicare payment models built on the same principle were at that point published but not finalized. Democrats on the Senate Finance Committee, meanwhile, spent the spring writing to manufacturers — including a March letter to GSK — demanding to know how the pricing commitments actually operate and how they interact with existing Medicaid rebate law.
Those are fair questions, and they cut in an uncomfortable direction for the people asking them. The transparency complaint is real: nobody outside the executive branch has seen these contracts. But the practical answer to an agreement that a future president could cancel is to pass it into statute, and the same members raising the alarm have not supplied the votes to do it. Twenty-six companies and 89% of the branded market are currently held in place by a tariff schedule and a signature. That is a remarkable amount of leverage for one administration to have assembled. It is also exactly as durable as the next election makes it.
This article was researched and drafted with the assistance of AI tools, with sourcing verified against primary government documents.
Nathaniel Cross focuses on retirement planning, employer benefits, and long-term income security. His writing covers pensions, social programs, investment vehicles, and strategies designed to protect financial independence later in life. At The Daily Overview, Nathaniel provides practical insight to help readers plan with confidence and foresight.
